Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04085510Not ApplicableActive Not Recruiting

Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania

Role: lead

NCT06105749Not ApplicableRecruiting

Biennial CEM in Women With a Personal History of Breast Cancer

Role: lead

NCT04764292Phase 4Completed

Screening Contrast-Enhanced Mammography as an Alternative to MRI

Role: lead

NCT02643966Not ApplicableCompleted

Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT

Role: lead

All 4 trials loaded